Amoéba

AGM Information • Jan 30, 2020

Amoéba announces the second convening of its Shareholders' Meeting

Chassieu (France), January 30, 2020 - AMOÉBA (FR0011051598 - AMEBA), producer of a biological biocide, capable of eliminating bacterial risk in water and human wounds, and a biocontrol product for plant protection, still in the testing phase, informs that the Ordinary and Extraordinary General Meeting held today at 10 a.m., at the Company's registered office, could not be held for lack of quorum both for resolutions falling within the competence of the Ordinary and Extraordinary General Meeting.

Consequently, and in accordance with legal provisions, the Company's shareholders are hereby notified of the holding of an Ordinary and Extraordinary Shareholders' Meeting convened on second call, on Friday 13 March 2020 at 10 a.m. at the Company's registered office at 38 avenue des Frères Montgolfier- 69680 Chassieu.

In accordance with the provisions of articles R. 225-77 and R. 225-79 of the French Commercial Code, the postal voting forms sent to the Company and the mandates given for the Combined General Meeting of 30 January 2020 on first convocation remain valid for the Ordinary and Extraordinary General Meeting convened on second convocation on the same agenda as long as the accounting registration of the shares is maintained.

The notice of the second convocation including the agenda will be published in the next few days in the Bulletin des Annonces Légales Obligatoires (BALO) and posted on the Company's website.

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial risk in the fields of water, healthcare and plant protection. Our biological solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn (1) on a global chemical biocide market for water treatment, evaluated at €21Bn (2) and on the biocontrol market for plant protection estimated globally at €1.6Bn (4) . In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million (3) in the USA. Sales of associated products with healthcare, biocides and crop protection are subject to the Company being granted local regulatory market authorizations. The Company is currently in a trial phase for biocidal and plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on www.amoebabiocide.com.

• (1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
• (2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et MarketsandMarkets
• (3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017
• (4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba

Valérie FILIATRE General Manager +33 (0)4 26 69 16 00 valerie.filiatre@amoeba-biocide.com

Investors Relations Grégory BOSSON Agence Calyptus +33(0)1 53 65 37 90 gregory.bosson@calyptus.net

Medias relations

Constance LOZET Agence Ekno +33(0)7 78 41 19 70 constance.lozet@ekno.fr

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 25, 2019 under number D19-0383 (a copy of which is available on www.amoeba-biocide.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.